metabolism of vabicaserin in mice, rats,...
TRANSCRIPT
1
METABOLISM OF VABICASERIN IN MICE, RATS, DOGS, MONKEYS AND HUMANS
Zeen Tong, Appavu Chandrasekaran, William DeMaio, Robert Espina, Wei Lu, Ronald Jordan,
and JoAnn Scatina
Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426.
DMD # 33670 DMD Fast Forward. Published on August 25, 2010 as doi:10.1124/dmd.110.033670
Copyright 2010 by the American Society for Pharmacology and Experimental Therapeutics.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
2
Running title: Metabolism of vabicaserin
Corresponding author:
William DeMaio
4 Wynnewood Dr
Collegeville, PA 19426
Phone: (484)902-0306
Fax: none
E-mail: [email protected]
Numbers of pages:
Number of tables: 5
Number of Figures: 10
Number of references: 19
Number of words: Abstract: 237; Introduction: 402; Discussion: 700.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
3
Abstract
Vabicaserin is a potent 5-HT2C agonist that is currently being developed for the treatment of the
psychotic symptoms of schizophrenia. In this study, in vitro and in vivo metabolism of
vabicaserin was evaluated in mice, rats, dogs, monkeys and humans, and the structures of the
metabolites were characterized by LC/MS and NMR spectroscopy. Vabicaserin underwent three
major metabolic pathways in vitro: NADPH-dependent hydroxylation, NADPH-independent
imine formation and carbamoyl glucuronidation. Following a single oral dose, vabicaserin was
extensively metabolized in animals and humans, and its metabolites were mainly excreted via the
urine in mice and rats. Along with the metabolites observed in vitro, secondary metabolism via
oxidation and conjugation of the primary metabolites generated from the above mentioned three
pathways yielded a number of additional metabolites in vivo. Carbamoyl glucuronidation was
the major metabolic pathway in humans, but a minor pathway in rats. Although carbamoyl
glucuronidation was a major metabolic pathway in mice, dogs and monkeys, oxidative
metabolism was also extensive in these species. Hydroxylation occurred in all species, although
different regional selectivity was apparent. The imine pathway also appeared to be common to
several species, since vabicaserin imine was observed in humans and hydroxyl imine metabolites
were observed in mice, rats and dogs. A nitrone metabolite of vabicaserin was observed in dogs
and humans but not in other species. In conclusion, the major metabolic pathways for
vabicaserin in humans and non-clinical safety species include carbamoyl glucuronidation,
hydroxylation, formation of an imine and a nitrone.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
4
Introduction
Recent studies have demonstrated that 5-HT2C agonists decrease levels of dopamine in the
prefrontal cortex and nucleus accumbens, brain regions that are thought to mediate the critical
effects of antipsychotic drugs (Millan et al., 1998; DiMatteo et al., 1999; DiGiovanni et al.,
2000). In contrast, 5-HT2C agonists do not decrease dopamine levels in the striatum, the brain
region most closely associated with extrapyramidal side effects (Millan et al., 1998; DiMatteo et
al., 1999). In addition, a recent study demonstrated that 5-HT2C agonists decrease firing in the
ventral tegmental area but not in the substantia nigra (DiMatteo et al., 1999; DiGiovanni et al.,
2000). The differential effects of 5-HT2C agonists in the mesolimbic pathway relative to the
nigrostriatal pathway suggests that 5-HT2C agonists have the potential to treat psychotic
symptoms with lower liability for the extrapyramidal side effects associated with typical
antipsychotics.
Vabicaserin is a potent 5-HT2C full agonist and demonstrates in vitro functional selectivity for 5-
HT2C over 5-HT2A and 5-HT2B receptors (Dunlop et al., 2006). Vabicaserin is effective in
several animal models that are predictive of antipsychotic activity, with an atypical antipsychotic
profile (Marquis et al., 2006). Administration of vabicaserin decreases nucleus accumbens
dopamine levels without affecting striatal dopamine, which is indicative of mesolimbic
selectivity. This profile is consistent with potential efficacy in the treatment of the psychotic
symptoms of schizophrenia with decreased liability for extrapyramidal side effects. In addition,
chronic administration of vabicaserin significantly decreases the number of spontaneously active
mesocorticolimbic dopamine neurons, without affecting nigrostriatal dopamine neurons,
consistent with the effects of atypical antipsychotics.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
5
Formation of a carbamoyl glucuronide (CG) was the major metabolic pathway in human liver
microsomes with bicarbonate buffer and a CO2-enriched environment in the presence of both
NADPH and UDPGA (Tong et al., 2010). Following a single oral dose to healthy human
volunteers, the carbamoyl glucuronide (CG) was the predominant metabolite in human plasma
and urine, with average CG-to-vabicaserin concentration ratios ranging from 8 to 74 in plasma
and 96 to 537 in urine (Tong et al., 2010). However, oxidative metabolism also appeared to be
occurring in vitro in liver microsomes (Tong et al., 2010). Although, the in vivo formation of
oxidative metabolites was evident from their presence in plasma and urine, the structures of
those metabolites were previously not established due to limited availability of human biological
samples (Tong et al., 2010). Therefore, the purpose of the current study was to generate and
isolate sufficient amounts of these oxidative metabolites, elucidate the structures of the major
vabicaserin metabolites by LC/MS and NMR spectroscopy, determine mass balance in the safety
species and compare in vitro and in vivo metabolite profiles of vabicaserin in humans and non-
clinical safety species.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
6
Materials and Methods
Materials. [14C]Vabicaserin hydrochloride {(9aR, 12aS)-4, 5, 6, 7, 9, 9a, 10, 11, 12, 12a-
decahydro-cyclopenta[c][1, 4]diazepino[6, 7, 1-ij]quinoline} was synthesized by the
Radiosynthesis Group, Chemical Development, Wyeth (now Pfizer, Pearl River, NY). The
radiochemical purity of [14C]vabicaserin was 98.9% and the chemical purity was 99.9% by UV
detection. The specific activity of the [14C]vabicaserin was 222.9 μCi/mg as a hydrochloride
salt. Non-labeled vabicaserin hydrochloride with a chemical purity of 98.6% was synthesized by
Wyeth (Pearl River, NY). Vabicaserin CG (WAY-280107) was synthesized by Chemical
Development at Wyeth (Montreal, Quebec), and had a purity of 95.5%. The chemical structures
of [14C]vabicaserin and its CG are shown in Figure 1. Liver microsomes listed in Table 1 from
CD-1 mice, Sprague-Dawley rats, beagle dogs and cynomolgus monkeys were obtained from In
Vitro Technologies (Baltimore, MD). Pooled human liver microsomes from 10 subjects of
mixed sex were purchased from Xenotech, LLC (Lenexa, KS) (Table 1). Glucose-6-phosphate,
glucose-6-phosphate dehydrogenase, nicotinamide adenine dinucleotide phosphate (NADP+),
uridine 5′-diphosphoglucuronic acid trisodium salt (UDPGA), EDTA, 3-chloroperoxybenzoic
acid (mCPBA, 77%), silica gel (230-400 mesh) and Fluka silica gel TLC plates were obtained
from Sigma-Aldrich (St. Louis, MO). Acetonitrile, ethyl acetate and methanol were HPLC or
ACS reagent grade and were purchased from EMD Chemicals (Gibbstown, NJ). Ultima Gold
and Ultima Flo scintillation cocktails were purchased from PerkinElmer (Wellesley, MA).
DMSO-d6 (D, 99.96%) was obtained from Cambridge Isotope Laboratories (Andover, MA).
Other chemicals of analytical grade and solvents of high performance liquid chromatography
(HPLC) grade were obtained from EMD Chemicals (Gibbstown, NJ) or Mallinckrodt Baker Inc.
(Phillipsburg, NJ).
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
7
Vabicaserin nitrone was synthesized for NMR spectroscopic analysis. At room temperature with
stirring, a solution of mCPBA (216 mg, about 1 mmol) in acetonitrile (75 mL) was slowly added
to a suspension of vabicaserin (230 mg, 1.0 mmol) in acetonitrile (100 mL) and kept stirring at
room temperature for 1 h. Then the reaction mixture was concentrated at room temperature
using a rotary vacuum evaporator. Fractionation by silica gel flash chromatography was
conducted with a gradient of ethyl acetate to ethyl acetate:methanol (6:1). The fraction
containing vabicaserin nitrone was condensed and further purified on a silica gel TLC plate using
a developing solvent system of ethyl acetate:methanol (6:1). The yellow band containing
vabicaserin nitrone (Rf =0.3) fluoresced under UV (365 nm) irradiation. This band was extracted
using methanol and evaporated to dryness under a stream of nitrogen yielding vabicaserin
nitrone (0.3 mg). LC/MS data for the synthetic material matched that obtained for P5 in human
plasma (data not shown).
Incubation with Liver Microsomes. In vitro incubations were conducted to isolate metabolites
by HPLC for structure elucidation as well as to evaluate in vitro metabolite profiles in various
species. In vitro incubations with liver microsomes of mouse, rat, dog, monkey and human in
the presence of NADPH and UDPGA were the same as previously described (Tong et al. 2010).
Briefly, [14C]vabicaserin (10 μM) was incubated for 20 min in a CO2-enriched environment with
liver microsomes (0.5 mg/mL) in 0.5 mL of 50 mM bicarbonate buffer, pH 7.4, containing
alamethicin (50 μg/mg protein) and magnesium chloride (10 mM), in the presence of an NADPH
regenerating system and UDPGA (2 mM). In addition, [14C]vabicaserin (10 μM) was also
incubated for 20 min with liver microsomes (0.5 mg/mL) in 0.1 M phosphate buffer containing
magnesium chloride (10 mM), pH 7.4, in the presence of the NADPH regenerating system, in
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
8
order to study the oxidative metabolism alone. The samples were prepared and analyzed as
previously described (Tong et al. 2010) by HPLC with radioactivity detection for metabolite
profiles and by LC/MS for metabolite identification. Vabicaserin metabolites were isolated for
analysis by NMR spectroscopy.
Excretion Studies in Animals
All animal housing and care was conducted in Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) accredited facilities. Animal care and use for excretion and
metabolism studies were approved by the Wyeth Institutional Animal Care and Use Committee.
Animal rooms were maintained on a 12-hour light and dark cycle. Animals were provided food
and water ad libitum.
Rats: Four male Sprague-Dawley rats, obtained from Charles River Laboratories (Wilmington,
MA), were used in this study. The animal body weights ranged from 337 to 348 g on the day of
dosing. The dose vehicle contained 2% Tween-80 and 0.5% methylcellulose in water.
Appropriate amounts of [14C]vabicaserin and non-labeled vabicaserin were dissolved in the dose
vehicle to give a solution. The final concentration of vabicaserin was approximately 2 mg/mL.
All animals (n=4) received a targeted single oral dose of 5 mg/kg (80.7 μCi/kg) via intragastric
gavage at a volume of 2.5 mL/kg. Urine and feces were collected for 120 h from all animals
following administration of [14C]vabicaserin. Urine samples were collected at ambient
temperature at intervals of 0-8, 8-24, 24-48, 48-72, 72-96, and 96-120 h post-dosing. Fecal
samples were collected at ambient temperature at intervals of 0-24, 24-48, 48-72, 72-96 and
96-120 h post-dosing. Cage rinses were collected at intervals of 0-24, 24-72 and 72-120 h by
rinsing each cage with approximately 100 mL of 30% ethanol in water.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
9
Bile study in rats: Four male rats weighing from 387 to 411 g and four female rats weighing
from 291 to 325 g at the time of dosing were purchased from Charles River Laboratories
(Wilmington, MA), and bile-duct cannulation was performed in-house. The dose vehicle was the
same as in the excretion study. On the day of dosing, [14C]vabicaserin and non-labeled
vabicaserin were dissolved in the vehicle to a final concentration of approximately 1 mg/mL.
Non-fasted rats were given a single 5 mg/kg (323 μCi/kg) target dose of vabicaserin at a volume
of 5.0 mL/kg via intragastric gavage. Animals were provided standard rat chow and water ad
libitum, and were kept in metabolism cages individually.
Bile was collected into tubes on dry ice at 0-4, 4-8, 8-24 and 24-48 h intervals post-dosing.
Feces and urine were collected into containers on dry ice at 0-24 and 24-48 h intervals.
All biological samples and aliquots from the pre-dosing and post-dosing formulation were stored
at approximately -70°C until analyzed.
Dogs: Four male beagle dogs, weighing from 7.6 to 9.8 kg at the time of dosing, were from an
in-house colony. [14C]Vabicaserin hydrochloride and of non-labeled vabicaserin hydrochloride
were dissolved in methanol and then evaporated under a nitrogen stream to dryness. Capsules
(#2) were filled with accurate amounts (approximately 130 mg) of the mixed drug substance
according to animal weights to give a dosage of 15 mg/kg (39 μCi/kg). The filled gelatin
capsules were then enteric-coated manually. Each dog was given one enteric-coated capsule
containing [14C]vabicaserin as a hydrochloride salt. Animals were fed two hours prior to dosing
and provided Purina dog chow and water ad libitum, and were housed individually in metabolic
cages.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
10
Urine samples were collected at intervals of 0-8, 8-24 and 24-48 h into tubes on dry ice, and at
intervals of 48-72, 72-96, 96-120, 120-144 and 144-168 h post-dosing at room temperature.
Fecal samples were collected at ambient temperature at intervals of 0-8, 8-24, 24-48, 48-72,
72-96, 96-120, 120-144 and 144-168 h post-dosing. Cage rinses were collected daily by rinsing
each cage with approximately 250-1100 mL of 30% ethanol in water.
In Vivo Metabolism
For metabolism studies in male mice, rats and dogs, radio-labeled doses were used. Male CD-1
mice and Sprague-Dawley rats were purchased from Charles River Laboratories (Wilmington,
MA). The dose vehicle for mice and rats contained 2% (w/w) Tween 80 and
0.5% methylcellulose in water. Twenty (five/time point) non-fasted male mice weighing from
28 to 34 grams at the time of dosing were given a single 50 mg/kg (~300 μCi/kg) dose of
vabicaserin at a volume of 20 mL/kg via intragastric gavage. Mice were kept in metabolic cages
in groups of five. Twelve (three/time point) non-fasted male rats weighing from approximately
320 to 350 grams at the time of dosing were given a single 5 mg/kg (~300 μCi/kg) dose of
vabicaserin at a volume of 2.5 mL/kg via intragastric gavage. Rats were kept individually in
metabolism cages. Dog plasma, urine and feces for metabolite profiling were collected from the
same animals used in the excretion study described earlier.
Four male cynomolgus monkeys, weighing from approximately 5 to 10 kg at the time of dosing,
were from an in-house colony. Non-fasted monkeys were given a single 25 mg/kg dose of non-
radiolabeled vabicaserin at a volume of 2 mL/kg via intragastric gavage. The vehicle was the
same as used in mice and rats. Animals were housed individually in metabolic cages.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
11
Blood samples were collected from mice and rats at sacrifice by cardiac puncture at 2, 4, 8 and
24 h post-dosing. Blood samples of about 3 mL from the jugular vein of dogs and from the
femoral trigon of monkeys were collected at 2, 4, 8 and 24 h post-dosing. Potassium EDTA was
used as the anticoagulant and plasma was immediately harvested from the blood by
centrifugation at 4°C. Urine samples were collected from animals at 0-8 and 8-24 h intervals for
all species. Fecal samples were collected at 0-24 h post-dosing. Urine and feces were also
collected 24-48 h post-dose from dogs. All biological specimens were stored at approximately -
70°C until analysis.
Dosing and sample collections from humans were conducted at a single investigational site
(Methodist Hospital, Philadelphia, PA). Oral doses of vabicaserin capsules of 500 mg were
administered to three healthy male subjects under fasting conditions. Plasma samples were
collected within two hours before test article administration (pre-dose), and at 6, 12 and 24 h
post-dose for metabolite profiling. Urine specimens were collected at intervals of 0-4, 4-12 and
12-24 h. Samples were stored at approximately -70°C until analysis.
For human studies, the protocol and the informed consent forms (ICFs) were reviewed and
approved by the study site institutional review board (IRB). Subsequent amendments to the
protocols and/or any revisions to the ICFs were also reviewed and approved by the IRB. This
study was conducted in accordance with ethical principles that have origins in the Declaration of
Helsinki and in any amendments that were in place when the study was conducted. Written
informed consent was obtained from all subjects before their enrollment.
Radioactivity Determination for Mouse, Rat and Dog Studies. Plasma (10 μL) and urine
(100 μL) aliquots were analyzed for radioactivity concentrations. Each urine sample was mixed
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
12
and triplicate aliquots (100 or 200 μL) were analyzed for radioactivity concentrations. Prior to
analysis, cage rinses were weighed and mixed. Triplicate aliquots (100 or 200 μL) were weighed
and analyzed to determine the concentration of radioactivity. Radioactivity in plasma, urine and
cage rinses were determined with a Tri-Carb Model 3100 TR/LL liquid scintillation counter
(LSC) (PerkinElmer) using 5 mL of Ultima Gold as the scintillation fluid. Fecal samples were
weighed and homogenized in water at volume-to-weight ratios of about 5:1, and homogenates
(0.1-0.3 g) were placed on Combusto-cones with Combusto-pads and combusted. A model
307 Tri-Carb Sample Oxidizer, equipped with an Oximate-80 Robotic Automatic Sampler
(PerkinElmer), was used for combustion. The liberated 14CO2 was trapped with Carbo-Sorb E
carbon dioxide absorber, mixed with PermaFluor® E+ liquid scintillation cocktail, and counted in
a Tri-Carb Model 3100 TR/LL liquid scintillation counter (PerkinElmer). The oxidation
efficiency of the oxidizer was 97.7%.
Sample Preparation for Metabolite Profiling and Metabolite Identification. Plasma samples
were pooled by mixing an equal volume from each animal for each time point, and processed as
previously described (Tong et al., 2010). Briefly, aliquots of pooled plasma were mixed with
two volumes of methanol, placed on ice for about 5 min and then centrifuged. The supernatant
was transferred to a clean tube and evaporated at 22°C under nitrogen in a TurboVap LV
(Caliper Life Sciences) to a volume of about 0.3 mL. The concentrated extracts were
centrifuged, the supernatant volumes measured, and duplicate 10 μL aliquots analyzed by LSC
for extraction efficiency. Extraction efficiency was determined by comparing the total
radioactivity in the extracts versus that in the samples prior to extraction. An average of greater
than 80% of the plasma radioactivity was recovered in the extracts. The 24 h plasma samples
from mice, rats and dogs were not analyzed due to low radioactivity concentration. Urine
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
13
samples were pooled in a proportional manner to give 0-24 h samples for mouse, rat and dog.
Pooled urine samples were analyzed without further preparation.
Fecal homogenates were pooled proportionally to their weight to give 0-24 h samples for mouse,
rat and dog. Aliquots of 1 g of the pooled fecal homogenate were mixed with 2 mL methanol,
placed on ice for about 10 min and centrifuged. The supernatant was transferred to a clean tube.
The residue was extracted three times with 2 mL of a water:methanol (3:7) mixture. The
supernatants from each sample were combined, evaporated to about 1 mL, and centrifuged.
Extraction efficiency was determined by analyzing aliquots of 10 μL of the supernatant, by
comparing the total radioactivity in the extracts versus the total radioactivity in the samples prior
to extraction. An average of greater than 70% of the fecal radioactivity was extracted. Monkey
and human fecal samples were not analyzed.
Aliquots of urine and extracts of plasma and fecal samples were analyzed by HPLC with
radioactivity detection described below for metabolite profiles and by LC/MS for metabolite
characterization.
High Performance Liquid Chromatography (HPLC). A Waters model 2695 HPLC system
(Waters Corp., Milford, MA) with a built-in autosampler was used for metabolite isolation and
analysis for metabolite profiles. Separations were accomplished on a Luna C18(2) column
(150 x 2.0 mm, 5 μm) (Phenomenex, Torrance, CA) coupled with a guard (4 x 2 mm) cartridge.
The sample chamber of the autosampler was maintained at 4°C, while the column was at an
ambient temperature of about 20°C. Radioactivity chromatograms were recorded as described
above. The mobile phase consisted of 10 mM ammonium acetate, pH 4.5 (A) and methanol (B)
and was delivered at 0.2 mL/min. The linear gradients used are listed in Table 2 for each study.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
14
The HPLC eluent was collected at 20 s intervals into 96-well Lumaplates (PerkinElmer) due to
low radioactivity concentrations in mouse and dog plasma samples. The plates were dried
overnight in an oven at 40°C and analyzed by the TopCount NXT radiometric microplate reader.
For other radioactive animal samples and in vitro incubations, a Flo-One β Model A525
radioactivity detector with a 250 μL flow cell was used for data acquisition. The flow rate of
Ultima Flow M scintillation fluid was 1 mL/min, providing a mixing ratio of scintillation
cocktail to mobile phase of 5:1.
Liquid Chromatography/Mass Spectrometry (LC/MS). For metabolite characterization, the
HPLC conditions were the same as described above, except that Agilent model 1100 (Agilent
Technologies, Palo Alto, CA), Waters 2695 and Acquity UPLC (Waters) liquid chromatography
systems were used. UV spectra were recorded with diode array UV detectors for all analyses.
Most of the LC/MS analyses were conducted with mobile phase Gradient C (Table 2). Mass
spectral data for vabicaserin and its metabolites were obtained with LCQ ion trap (Thermo, San
Jose, CA), quadrupole time-of-flight (Q-TOF) (Waters) and triple quadrupole (Waters) mass
spectrometers. Each mass spectrometer was equipped with an electrospray ionization source and
operated in the positive ionization mode. Settings for each mass spectrometer were optimized to
provide a structurally relevant range of product ions from MS/MS and MSn experiments.
Product ion spectra recorded with the triple quadrupole mass spectrometer employing a collision
energy setting of 22 eV were used as the reference spectra to confirm metabolite identifications.
MassLynx (versions 3.5, 4.0, and 4.1, Waters) and Xcalibur (version 1.3, Thermo) software were
used for collection and analysis of LC/MS data.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
15
Nuclear Magnetic Resonance (NMR) Spectroscopy. Vabicaserin metabolites P1, P2, P3, P4,
P5, P6 and CG were isolated, concentrated and re-purified using the same HPLC conditions as
above except that 0.1% formic acid in water was used as mobile phase A and 0.1% formic acid
in methanol was used as mobile phase B. Vabicaserin metabolites P7, P9 and P10 were isolated
from rat urine by HPLC with an ammonium acetate mobile phase followed by HPLC with a
trifluoroacetic acid mobile phase. Each isolated metabolite was evaporated to dryness under a
nitrogen stream. Vabicaserin metabolites P1, P2, P3, P4, P5 and P6 were dissolved in 500 μL
DMSO-d6 and transferred into a 5 mm NMR tube. NMR spectroscopic data were recorded at
30ºC on a 600 MHz Bruker Avance III spectrometer with a 5 mm CPTCI CryoProbe™ (Bruker
BioSpin Corporation, Billerica, MA). Proton, HSQC, and HMBC experiments were performed.
All chemical shifts were referenced to the DMSO signal at 1H δ 2.49 ppm and 13C δ 39.5 ppm.
The proton spectra were acquired with 32,768 data points over a 6,602 Hz spectral window using
a 30º pulse and standard pulse sequence. Data were Fourier transformed with a 0.3 Hz line
broadening window function. The 2D 1H-13C HSQC spectra were acquired with 1024 data
points in F2, and 256 increments in F1, with 32 scans per increment, using a phase sensitive pulse
sequence. The 2D 1H-13C HMBC spectra were acquired with 4096 data points in F2, and 256
increments in F1 with 64 scans per increment. Vabicaserin metabolites P7, P9 and P10 were
dissolved in 150 μL DMSO-d6 and transferred into a 3 mm NMR tube. One-dimensional (1D)
proton NMR and two-dimensional (2D) NMR (COSY, ROESY) data were collected on an Inova
500 MHz NMR spectrometer (Varian, Palo Alto, CA) equipped with a Nalorac 5 mm z-gradient
indirect detection probe (Varian).
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
16
Results
Metabolite Characterization. Mass spectral data for vabicaserin and its metabolites are
summarized in Table 3. Based on their molecular ions and fragmentations in comparison to
vabicaserin, the proposed structures of metabolites are presented in Figure 1. Vabicaserin
metabolites were isolated by HPLC from in vitro incubations (P1, P2, P3, P4, P5, P6 and CG)
and from rat urine (P7, P9 and P10) for analysis by LC-MS/MS and NMR spectroscopy, and the
structures of the aforementioned metabolites were confirmed by NMR spectroscopic data from
1H and 13C (1H-1H COSY, 1H-13C HSQC, and 1H-13C HMBC) (Table 4). HPLC retention time
and mass spectral data for CG matched those for the synthetic carbamoyl glucuronide of
vabicaserin.
In Vitro Metabolite Profiles
Radiochromatographic profiles of [14C]vabicaserin (10 μM) following incubation with human
liver microsomes in the absence and presence of the NADPH regenerating system, and in the
presence of both NADPH and UDPGA are depicted in Figure 2. When [14C]vabicaserin was
incubated with human liver microsomes in phosphate buffer in the presence of NADPH, five
metabolites (P1-P5) were detected. Formation of P6 required microsomes, but was not NADPH-
dependent. Metabolites P1, P2, P3 and P4 were characterized by LC/MS and NMR spectroscopy
as hydroxyl vabicaserin, P5 as vabicaserin nitrone and P6 as vabicaserin imine. When
[14C]vabicaserin was incubated with human liver microsomes in bicarbonate buffer and a CO2-
enriched environment in the presence of both NADPH and UDPGA, a new product (CG) was
detected with higher abundance than any of the other aforementioned metabolites. CG was
identified as vabicaserin carbamoyl glucuronide by LC/MS analysis and comparison with the
synthetic carbamoyl glucuronide.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
17
Radiochromatographic profiles of [14C]vabicaserin following incubation at a concentration of 10
μM with mouse, rat, dog and monkey liver microsomes in presence of both NADPH and
UDPGA are shown in Figure 3. Although quantitative differences among the various species
investigated were apparent, the in vitro metabolite profiles of vabicaserin were qualitatively
similar across the species (Figures 2 and 3), and all human metabolites were detected in one or
more animal species. Monkey liver microsomes generated similar profiles to those of humans,
except that P2 was detected in relatively higher intensity, while P6 was observed in relatively
lower intensity than in human liver microsomes. However, as the purpose of the in vitro study
was to generate metabolites for structural elucidation and for qualitative profiling, the in vitro
incubation conditions were not optimized for each species to provide in vitro and in vivo
extrapolation.
Excretion
Mice: Excretion of radioactivity was determined in the samples collected up to 24 h following
oral administration of 50 mg/kg [14C]vabicaserin to male CD-1 mice in the metabolism study.
Urine was the major route of excretion, with 59.6% of the radioactive dose recovered in the 24 h
post-dose. Fecal elimination in the first 24 h post-dose accounted for 13.6% of the dosed
radioactivity.
Rats: The excretion of radioactivity in male Sprague-Dawley rats was evaluated after a single
oral (gavage) dosage of 5 mg/kg [14C]vabicaserin. The total recovery of radioactivity (feces,
urine, and cage rinse) over a period of 5 days (120 h) was 93.8%. The major route of excretion
of radioactivity was the urine (64.3%); fecal excretion was relatively minor (28.0%). The rate of
excretion of radioactivity was rapid, with 87.4% of the oral dose recovered in urine and feces
(including cage rinse) in the first 24 h after dosing.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
18
Biliary excretion in rats: Excretion of radioactivity was also determined in bile-duct cannulated
rats after a single oral 5 mg/kg dose of [14C]vabicaserin. Urine was the major excretion route for
vabicaserin related radioactivity after a single oral dose, while biliary excretion was relatively
minor. In the first 48 h post-dosing, an average of 60% of the radioactive dose was excreted in
the urine, while an average of 17% of the administered radioactivity was excreted in the bile.
Excretion of radioactivity in rats was rapid, with the majority of the radioactivity recovered in
the first 24 h post-dosing. These results were consistent with the finding in the mass balance
study, where 64% of the administered radioactivity was recovered in urine.
Dogs: The excretion of radioactivity in male beagle dogs was evaluated after a single oral
(enteric-coated capsule) dose of 15 mg/kg of [14C]vabicaserin. The total recovery of
radioactivity (feces, urine, and cage rinse) over a period of 7 days (168 h) was 97.3%. Large
individual variations in daily recovery were observed. The major route of excretion of
radioactivity was the feces (58.5%); urinary excretion was relatively minor (32.7%). The rate of
excretion of radioactivity was rapid, with 84.2% of the oral dose recovered in urine and feces
(including cage rinse) in the first 48 h after dosing, which may have been due to the enteric
coating affecting the release of vabicaserin.
In Vivo Metabolite Profiles
Representative radiochromatographic profiles of plasma and urine samples of mice, rats and
dogs administered a single oral dose of [14C]vabicaserin are depicted in Figures 4-6. Vabicaserin
was extensively metabolized in all three species, with the parent drug representing less than 21%
of the total plasma radioactivity. Estimated concentrations of vabicaserin and its metabolites
observed in plasma of mice, rats and dogs following oral administration of [14C]vabicaserin are
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
19
summarized in Table 5. Percentages of vabicaserin and its metabolites in urine of various
species as determined by their chromatographic distribution are summarized in Table 6.
In mice, vabicaserin, CG and hydroxyl vabicaserin (P2 and P3) were the major radioactive
components in plasma (Figure 4). Vabicaserin represented no more than 1.2% of the
administered radioactive dose in urine. Hydroxyl vabicaserin (P2 and P3), hydroxyl vabicaserin
glucuronide (P9), didehydrohydroxyl vabicaserin glucuronide (P19), and CG were the major
metabolites in mouse urine. Unchanged vabicaserin represented 18% of fecal radioactivity in 0
to 8 h post-dose and 11% for 8 to 24 h post-dose samples. Hydroxyl vabicaserin (P2 and P3),
keto vabicaserin (P7), hydroxyl vabicaserin imine sulfate (P8), hydroxyl vabicaserin sulfate
(P10), and hydroxyl vabicaserin imine (P14) were identified in feces. CG was not observed in
mice feces, likely because of cleavage in the gastrointestinal tract.
In rats, vabicaserin was extensively metabolized to predominantly oxidative metabolites.
Unchanged vabicaserin represented ≤ 20% of the total radioactivity in plasma and < 1% of the
administered radioactive dose in urine. Hydroxyl vabicaserin (P1, P2 and P3) and keto
vabicaserin (P7) were the major drug-related components in rat plasma (Figure 5). The hydroxyl
metabolites (P1 and P3), keto vabicaserin (P7), and the glucuronide (P9) were the major
metabolites in urine. CG was not detected in rat plasma or urine. Metabolites P3, P8, P10, and
P11 and only trace amounts of vabicaserin were detected in rat feces.
In the biliary excretion and metabolite profile study in rats, vabicaserin represented an average of
< 3% of radioactivity in bile, and 3% to 4% of radioactivity in urine. Vabicaserin and its
metabolites were excreted in bile almost solely as conjugates. Biliary metabolite profiles did not
change significantly over time. The major biliary metabolites included CG, hydroxyl vabicaserin
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
20
imine sulfate (P8), hydroxyl vabicaserin glucuronides (P9 and P24), N-acetyl hydroxyl
vabicaserin (P12), and hydroxyl vabicaserin carbamoyl glucuronide (P21). CG, which was not
detected in plasma or urine, was the most abundant metabolite in bile, representing 22% to 30%
of the radioactivity in bile. Urinary metabolites included hydroxyl vabicaserin (P1, P2, P3, and
P4), keto vabicaserin (P7), hydroxyl vabicaserin imine sulfate (P8), hydroxyl vabicaserin sulfate
(P10), hydroxyl vabicaserin glucuronide (P9), and N-acetyl hydroxyl vabicaserin (P12).
In dogs, vabicaserin was extensively metabolized after administration of an enteric-coated
capsule containing [14C]vabicaserin. Oxidative metabolism was the major metabolic pathway,
while formation of CG was also observed. Vabicaserin represented < 21% of the radioactivity in
plasma and no more than 0.5% of the administered radioactive dose in urine, similar to mice and
rats. In dog plasma, vabicaserin, CG, P1, P2, P3 as well as hydroxyl vabicaserin imine (P13)
were the major drug-related components. Metabolites observed in dog plasma were also detected
in dog urine. A hydroxyl vabicaserin sulfate (P17) and a diazepinyl vabicaserin carboxylic acid
(P18), which was not detected in plasma, were observed in urine. Hydroxyl vabicaserin
metabolites (P2, P3, and P20), a keto vabicaserin (P7), and a hydroxyl vabicaserin imine (M15)
were detected in fecal extracts. Some metabolites of vabicaserin differed in dogs compared with
those in rats. Sulfate metabolites were less abundant in dogs, and CG was detected in dogs but
not in rats.
Representative summed mass chromatograms of plasma and urine samples obtained from
monkeys and humans following oral administration vabicaserin are shown in Figures 7 and 8.
Non-labeled material was administered to monkeys and humans, and oxidative metabolites were
not quantified in these samples. In monkeys, vabicaserin was extensively metabolized via both
phase I and II metabolism. In monkey plasma, along with the metabolites observed in the in
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
21
vitro incubation with monkey liver microsomes, additional oxidative metabolites (P20 and P25)
were present (Figure 7).
After oral (capsule) administration of vabicaserin to humans, vabicaserin was extensively
metabolized, primarily to the carbamoyl glucuronide (CG). Vabicaserin nitrone (P5) was
observed in humans, as seen in dog plasma (Figures 6 and 8). Generally, urinary metabolite
profiles were similar to plasma profiles (Figures 7-8). A number of metabolites, which were not
detected in in vitro incubations, were observed in plasma and/or urine of humans and animal
species examined. These were the secondary metabolite formed through oxidative metabolism
and conjugation of the primary metabolites of hydroxylation, imine formation or carbamoyl
glucuronidation.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
22
Discussion
The present study indicated that vabicaserin undergoes NADPH-dependent oxidative metabolism
to form hydroxyl metabolites (P1-P4), NADPH-independent formation of an imine (P6) as well
as UGT-catalyzed formation of a carbamoyl glucuronide (CG) in a CO2 enriched environment in
human liver preparations (Figure 9). Vabicaserin nitrone (P5) was generated directly from
vabicaserin or from P6 in human liver microsomes in the presence of NADPH.
Radioactivity was eliminated rapidly in mice (73.2% in 24 h), rats (87.4% in 24 h) and dogs
(84.2% in 48 h) following oral administration of [14C]vabicaserin. Urine was the major route of
elimination of the dosed radioactivity following oral administration of [14C]vabicaserin to mice
and rats, while fecal elimination was the major route of excretion in dogs. Since non-
radiolabeled vabicaserin was administered to monkeys and humans, excretion of total drug
derived materials could not be determined. However, quantitative data obtained by LC/MS
analysis indicated that less than 1% of the oral dose was eliminated as unchanged drug and >50%
of the administered dose was excreted as CG in urine of humans (Tong et al 2010).
Vabicaserin was extensively metabolized in all species and species differences were observed
following a single oral dose to humans and animals. Although a number of additional
metabolites were observed, in vivo metabolism of vabicaserin generally followed the same
metabolic pathways observed in vitro: hydroxylation, imine formation and carbamoyl
glucuronidation. Further metabolism of the primary metabolites through oxidative metabolism
and conjugation yielded additional metabolites. As previously discussed (Tong et al., 2010),
carbamoyl glucuronidation was the major metabolic pathway in humans, but a minor metabolic
pathway in rats. Carbamoyl glucuronidation was also a major metabolic pathway in mice, dogs
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
23
and monkeys. However, oxidative metabolism was also extensive in these species.
Hydroxylation reactions occurred in all species, although different regional selectivity seemed to
exist. Although vabicaserin imine was observed only in humans, secondary metabolites of the
imine were observed in all species except monkey, suggesting that this metabolic pathway also
exists in mice, rats and dogs. Vabicaserin nitrone (P5) was observed in dogs and humans but not
in the other species studied.
Vabicaserin is composed of a fused four-ring system, including benzene, diazepane, piperidine,
and cyclopentane rings. Few metabolites were observed as a result of oxidation on the benzene
ring or at positions of 6, 7, 8, and 9 (Figure 1) even though these positions were considered an
electron rich region. Instead, oxidation occurred either on the cyclopentane ring with the
benzene and diazepane rings serving as the metabolic enzyme binding region to generate P1 to
P4, or on the diazepane ring with the other side of the molecule as the binding region for P450 or
other oxidation enzymes to form P5 and P6. Identification of enzymes responsible for
generating these metabolites is under investigation; as such information would be critical to
determine potential clinical drug-drug interactions.
In conclusion, vabicaserin was extensively metabolized in mice, rats, dogs, monkeys and humans
following oral administration. Urinary excretion was the major route of elimination of the dosed
radioactivity following oral administration of [14C]vabicaserin to mice and rats, while fecal
elimination was the major route of excretion in dogs. The structures of the metabolites isolated
and identified by LC/MS and NMR spectroscopic analysis from in vitro incubation of
vabicaserin with human liver microsomes indicated that vabicaserin metabolism involved three
major metabolic pathways: NADPH-dependent hydroxylation, NADPH-independent formation
of vabicaserin imine and carbamoyl glucuronidation.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
24
Acknowledgment
The authors thank Hongshan Li, Michael Carbonaro, C. Paul Wang, Abdul Mutlib, Theresa
Hultin and Rasmy Talaat for their contributions to these studies.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
25
References
Delbressine L, Funke C, van Tilborg M and Kaspersen F (1990) On the formation of carbamate glucuronides. Xenobiotica 20:133-134.
DiGiovanni G, DiMatteo V, DiMascio M and Esposito E (2000) Preferential modulation of mesolimbic vs nigrostriatal dopaminergic function by serotonin 2C/2B receptor antagonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53-61.
DiMatteo V, DiGiovanni G, DiMascio M and Esposito E (1999) SB 242084, a selective serotonin 2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195-1205.
Dunlop J, Zhang J, Watts S, Ramamoorthy S, Harrison B, Barrett JE, Magolda R, Schecheter L, Pangalos MN, Stack G and Rosenzweig-Lipson S (2006) In vitro pharmacological profile of SCA-136, a novel 5-HT2C receptor selective agonist. 36th Annual Meeting for the Society for Neuroscience (Washington, DC), Atlanta, GA, Oct 14-18.
Fenselau C (1994) Acyl glucuronides as chemically reactive intermediates. Hdbk Exp Pharmacol 112:367-389. Gipple K, Tung C, Elvin A, Lalka D and Alexon J (1982) Species differences in the urinary excretion of the novel
primary amine conjugate: tocainide carbamoyl-O-β-D-glucuronide. J Pharm Sci 71:1011-1014. Greenaway W and Whatley F (1987) Formation of N-carboxy compounds during trimethylsilanization of amino
acids in the presence of carbon dioxide. J Chromatography 409:383-389. Kilmartin J and Rossi-Bernardi L (1973) Interaction of hemoglobin with hydrogen ions, carbon dioxide and organic
phosphates. Physiol Rev 53:83-890. Marquis KL, Dunlop J, Ramamoorthy S, Beyer CE, Lin Q, Brennan J, Piesla MJ, Ashby CRJ, Harrison B, Magolda
R, Pangalos MN, Stack G and Rosenzweig-Lipson S (2006) SCA-136: a novel 5-HT2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. 36th Annual Meeting for the Society for Neuroscience (Washington, DC), Atlanta, GA, Oct 14-18.
Millan M, Dekeyne A and Gobert A (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953-955.
Morrow J, Keim P and Gurd F (1974) CO2 adducts of certain amino acids, peptides and whale myoglobin studied by carbon 13 and proton nuclear magnetic resonance. J Biol Chem 249:7484-7494.
Mroz E (1989) Possible role of carbamates in neurotoxicity and neurotransmitter inactivation. Science 243:1615. Schaefer W (1992) Formation of a carbamoyl glucuronide conjugate of carvedilol in vitro using dog and rat liver
microsomes. Drug Metabolism and Disposition 20:130-133. Schaefer W (2006) Reaction of primary and secondary amines to form carbamic acid glucuronides. Curr Drug
Metab 7:873-881. Senda C, Toda S, Tateishi M, Kobayashi K, Igarashi T and Chiba K (2003) Mexiletine carbonyloxy b-D-
glucuronide: a novel metabolite in human urine. Xenobiotica 8:871-884. Spahn-Langguth H and Benet L (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as
well as a detoxifixation mechanism? Drug Metab Rev. 24:5-47. Tremaine L, Stroh J and Ronfeld R (1989) Characterization of a carbamic acid ester glucuronide of the secondary
amine sertraline. Drug Metab Dispos 17:58-63. Tong Z, Chandrasekaran A, DeMaio W, Jordan R, Li H, Moore R, Poola N, Burghart P, Hultin T and Scatina J
(2010) Species differences in the fromation of vabicaserin carbamoyl glucuronide. Drug Metab Dispos 38:1-10.
Weiss J and Choi D (1988) Beta-N-methylamino-L-alanine neurotoxicity: requirements for bicarbonate as cofactor. Science 241:973-975.
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
26
Footnotes
Address correspondence to: Dr. William DeMaio, 4 Wynnewood Dr, Collegeville, PA 19426. E-
mail: [email protected]
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
27
Figure Legends Figure 1. Structures of vabicaserin and its metabolites
Figure 2. Incubations of [14C]vabicaserin (10 μM) with human liver microsomes in the absence
(A) and presence (B) of the NADPH regenerating system, and in the presence of both
NADPH and UDPGA (C)
Figure 3. Incubations of [14C]vabicaserin (10 μM) with liver microsomes in presence of both
NADPH and UDPGA
Figure 4. Radiochromatograms of Mouse Plasma (2 h) and Urine (0-24 h)
Figure 5. Radiochromatograms of Rat Plasma (2 h) and Urine (0-24 h)
Figure 6. Radiochromatograms of Dog Plasma (4 h) and Urine (0-24 h)
Figure 7. Summed Mass Chromatogram of Vabicaserin and its Metabolites in Pooled Monkey
Plasma (2 h) and Urine (0-24 h)
Figure 8. Summed Mass Chromatogram of Vabicaserin and its Metabolites in Human Plasma (6
h) and Urine (0-24 h)
Figure 9. In Vitro Metabolic Pathways of Vabicaserin in Humans
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
28
Table 1. Characteristics of mouse, rat, dog, monkey and human liver microsomes
utilized in this study
Species Sex
Number of Subjects
Pooled
P450 Content
(nmol/mg protein)
Mouse Male 20 0.40
Female 18 0.54
Rat Male 23 0.79
Female 50 0.55
Dog Male 5 0.57
Female 4 0.43
Monkey Male 10 1.17
Female 9 1.31
Human Male and female
mixed
10 0.36
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
29
Table 2. LC Gradients used for HPLC and LC/MS Analysis
Gradient A for analysis of in vitro samples Time (min) A (%) B (%)
0 90 10 3 90 10
25 60 40 45 15 85 50 15 85
Gradient B for analysis of rat and dog samples Time (min) A (%) B (%)
0 90 10 6 90 10
35 60 40 65 15 85
Gradient C for analysis of mouse, monkey and human samples Time (min) A (%) B (%)
0 95 5 3.0 95 5 3.1 90 10
13.0 90 10 25 80 20 50 70 30 51 50 50 70 10 90 80 10 90
DMD # 33670This article has not been copyedited and formatted. The final version may differ from this version.
DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670 at A
SPET
Journals on August 4, 2018
dmd.aspetjournals.org
Dow
nloaded from
30
Table 3. Mass spectral data for vabicaserin and its metabolites
Metabolite [M+H]+
Species/Matrixa
Relevant Product Ions (m/z) Mouse Rat Dog Monkey Human
Vabicaserin 229 P, U, F P, U, F, B P, U P, U P, U 212, 200, 187, 186, 158, 144, 132 P1 245 P, U P, U P, U P, U 228, 227, 216, 202, 186, 184, 158, 144 P2 245 P, U, F P, U P, U, F 228, 216, 202, 198, 184, 158, 144, 132 P3 245 P, U, F P, U, F P, U, F P P, U 228, 227, 216, 202, 198, 184, 158, 144, 132 P4 245 P, U 227, 198, 184, 156 P5 243 P, U P 226, 225, 198, 157, 130 P6 227 P, U 210, 198, 184, 156, 130 P7 243 P, U, F P, U P, U, F 226, 214, 200, 198, 158, 144, 132, 98 P8 325 P, U, F, B 283, 202, 184, 158, 144, 132 P9 421 P, U P, U, B P, U P, U 378, 245, 203, 202, 187, 160
P10 325 F P, U, F 283, 202, 184, 158, 144, 132 P11 245 P, U, F 186, 171, 158, 144 P12 287 P, U, B 269, 227, 186, 171, 158, 144 P13 243 P, U 187, 169, 130 P14 243 P, U, F P, U 226, 214, 200, 158, 144, 132, 98 P15 243 F 214, 200, 196, 182, 130 P16 243 P, U 214, 200, 196, 182, 130 P17 325 U 283, 282, 202, 184, 148 P18 257 U 213, 186, 171, 145, 130 P19 419 U P, U 243, 214, 202, 187 P20 245 F P, U P, U 228, 216, 186, 171 P21 465 B U 421, 289, 245, 228, 202, 184, 144 P22 421 U 404, 386, 362, 269, 228, 227, 210, 187 P23 421 U 360, 271, 245, 229, 228, 227, 212, 210, 200, 186 P24 421 B P, U 404, 378, 245, 228, 227, 202 P25 243 P, U 226, 214, 200, 132 CG 449 P B P, U P, U P, U 273, 229, 212, 186, 113
a. P, plasma; U, urine; F, feces; B, bile. Fecal samples from monkeys and humans were not analyzed for metabolite profiles.
DMD # 33670T
his article has not been copyedited and formatted. T
he final version may differ from
this version.D
MD
Fast Forward. Published on A
ugust 25, 2010 as DO
I: 10.1124/dmd.110.033670
at ASPET Journals on August 4, 2018 dmd.aspetjournals.org Downloaded from
31
Table 4. NMR spectroscopic data for vabicaserin and its metabolites
Metabolite 1H NMR (600 or 500 MHz, DMSO-d6) δ ppm 13C NMR δ ppm Vabicaserin 9.77 (1H, br. s.), 8.81 (1H, br. s.), 7.22 (1H, d, J=7.45 Hz), 7.16 (1H, d, J=7.45 Hz), 6.90 (1H, t, J=7.45 Hz),
4.18 (1H, d, J=13.70 Hz), 4.04 (1H, d, J=13.70 Hz), 3.39 (1H, dd, J=11.59, 4.33 Hz), 3.13 (3H, m), 3.04 (1H, dd, J=12.89, 4.43 Hz), 2.93 (1H, ddd, J=10.98, 7.56, 7.45 Hz), 2.64 (1H, t, J=12.89 Hz), 2.23 (1H, ddd,
J=11.99, 8.06, 3.73 Hz), 2.18 (1H, m), 1.99 (1H, td, J=12.89, 9.77 Hz), 1.64 (1H, m), 1.54 (1H, m, J=10.23, 10.10, 10.10, 2.42 Hz), 1.33 (1H, dd, J=11.89, 7.86 Hz), 1.25 (1H, m)
147.07, 131.57, 130.85, 128.66, 124.73, 121.03, 55.44,
51.94, 48.95, 46.98, 40.79, 34.1, 31.42, 28.81, 23.31
P1 7.06 (1H, dd), 7.01 (1H, dd, J=6.75, 0.50 Hz), 6.81 (1H, t, J=7.45 Hz), 4.67 (1H, d, J=4.84 Hz), 4.15 (1H, t, J=8.06 Hz), 3.92 (1H, m), 3.85 (1H, m), 3.18 (1H, d, J=13.50 Hz), 3.05 (1H, m), 2.95 (1H, m), 2.89 (1H, m), 2.83 (1H, t, J=12.59 Hz), 2.37 (1H, dd, J=6.65, 5.24 Hz), 2.19 (2H, m), 1.35 (1H, td, J=12.14, 8.97 Hz), 1.08
(1H, ddd, J=12.54, 6.60, 2.82 Hz).
147.15, 131.15, 130.03, 129.12, 127.03, 120.50, 70.19,
56.56, 54.89, 51.30, 48.99, 42.67, 38.12, 37.76, 30.50
P2 7.07 (1H, d, J=7.66 Hz), 6.98 (1H, d, J=7.45 Hz), 6.81 (1H, t, J=7.35 Hz), 4.53 (1H, d, J=1.01 Hz), 4.10 (1H, dd, J=10.88, 5.24 Hz), 3.89 (1H, d, J=14.51 Hz), 3.81 (1H, d, J=13.70 Hz), 3.39 (1H, d, J=8.46 Hz), 3.18 (1H,
d, J=1.41 Hz), 3.02 (1H, d, J=3.83 Hz), 2.99 (1H, m), 2.92 (2H, m), 2.55 (1H, t, J=12.89 Hz), 2.32 (1H, tt, J=8.26, 4.03 Hz), 2.09 (1H, dd, J=13.20, 6.95 Hz), 1.89 (1H, dd, J=14.51, 7.05 Hz), 1.46 (2H, m)
147.33, 131.37, 130.38, 128.96, 126.79, 120.49, 69.56,
56.06, 55.24, 51.66, 49.33, 43.03, 39.29, 37.71, 30.19
P3 8.21 (1H, br. s.), 7.05 (1H, d, J=7.45 Hz), 6.94 (1H, d, J=7.05 Hz), 6.78 (1H, t, J=7.45 Hz), 4.71 (1H, br. s.), 3.81 (1H, br. s.), 3.81 (1H, d, J=12.49 Hz), 3.77 (1H, d, J=13.30 Hz), 3.18 (1H, m), 3.12 (1H, d, J=9.47 Hz), 3.08 (1H, dd, J=13.20, 4.13 Hz), 2.99 (1H, m), 2.91 (1H, m, J=10.48, 10.48, 10.38, 10.17 Hz), 2.61 (1H, t,
J=12.59 Hz), 2.27 (1H, ddd, J=8.21, 3.98, 3.73 Hz), 2.03 (1H, m), 1.90 (1H, m), 1.48 (1H, dddd, J=17.73, 8.16, 4.73, 4.63 Hz), 1.35 (1H, m, J=12.95, 9.37, 9.09, 9.09 Hz)
128.74, 126.62, 120.46, 75.41, 56.21, 53.4, 52.11, 49.71, 41.96, 38.27, 33.36, 32.19
P4 7.36 (1H, dt, J=7.66, 0.91 Hz), 6.98 (1H, dd, J=6.35, 0.91 Hz), 6.81 (1H, t, J=7.45 Hz), 4.73 (1H, s), 3.81 (1H, d, J=14.10 Hz), 3.78 (1H, d, J=13.70 Hz), 3.16 (1H, dd, J=2.82, 1.41 Hz), 3.04 (1H, m), 2.99 (1H, dd, J=13.80, 4.73 Hz), 2.91 (1H, t, J=9.87 Hz), 2.81 (1H, dd, J=13.70, 11.89 Hz), 2.16 (1H, dd, J=11.59, 3.53 Hz), 2.04 (1H,
m), 1.98 (1H, ddd, J=12.59, 8.26, 1.91 Hz), 1.76 (1H, m), 1.68 (1H, dd, J=12.59, 8.76 Hz), 1.52 (1H, ddd, J=8.21, 3.98, 3.73 Hz), 1.21 (1H, m)
146.52, 134.92, 130.96, 127.68, 127.15, 120.29, 78.39,
57.69, 56.45, 52.00, 49.42, 40.56, 40.03, 27.36, 21.02
P5 7.71 (1H, s), 7.06 (1H, d, J=7.25 Hz), 7.04 (1H, d, J=7.66 Hz), 6.67 (1H, t, J=7.56 Hz), 4.12 (1H, dt, J=15.72, 4.63 Hz), 4.02 (1H, dt, J=15.72, 4.43 Hz), 3.50 (2H, m), 3.12 (1H, dd, J=12.09, 5.24 Hz), 2.94 (1H, dd,
J=17.73, 7.66 Hz), 2.83 (1H, dd, J=11.89, 10.48 Hz), 2.28 (1H, m), 2.13 (1H, m), 1.92 (1H, m), 1.62 (1H, m, J=16.22, 8.11, 8.11, 4.43 Hz), 1.52 (1H, dddd, J=19.90, 10.17, 10.02, 3.02 Hz), 1.42 (1H, m), 1.36 (1H, m)
144.39, 136.92, 130.05, 130.05, 128.83, 117.4, 115.35,
64.93, 53.15, 51.22, 40.49, 34.61, 34.47, 28.67, 22.34
P6 8.66 (1H, s), 7.58 (1H, dd, J=8.16, 1.31 Hz), 7.47 (1H, d, J=7.05 Hz), 6.81 (1H, dd, J=7.96, 7.15 Hz), 3.94 (1H, m), 3.86 (1H, m), 3.59 (2H, d, J=3.63 Hz), 3.40 (1H, dd, J=5.04, 2.62 Hz), 3.16 (1H, d, J=1.81 Hz), 3.02 (1H, m), 2.31 (1H, m), 2.11 (1H, dddd), 1.93 (1H, dddd, J=12.87, 5.54, 5.36, 1.81 Hz), 1.66 (1H, m), 1.59 (1H, m),
1.46 (1H, dd, J=12.49, 10.48 Hz), 1.41 (1H, m)
164.67, 150.06, 137.87, 137.03, 128.61, 116.78,
111.18, 54.11, 52.95, 51.28, 40.46, 33.87, 33.74, 27.97,
21.59 P7 9.10, 8.62, 7.35, 7.23, 7.01, 4.18, 4.15, 3.47, 3.34, 3.16 (dd), 3.20, 3.06, 3.01 (t), 2.59, 2.53, 2.32, 2.14, 1.76 NA P9 9.11, 8.55, 6.94, 6.91, 4.95, 4.18, 4.11, 3.84, 3.37, 3.02, 3.01, 2.93, 2.62, 2.24, 2.19, 2.00, 1.63, 1.52, 1.32, 1.23 NA P10 9.10, 8.62, 7.23, 7.15, 6.91, 4.29, 4.17, 4.14, 3.34, 3.23, 3.22, 3.20, 3.15, 3.14, 2.68, 2.40, 2.26, 1.97, 1.67, 1.33 NA
DMD # 33670T
his article has not been copyedited and formatted. T
he final version may differ from
this version.D
MD
Fast Forward. Published on A
ugust 25, 2010 as DO
I: 10.1124/dmd.110.033670
at ASPET Journals on August 4, 2018 dmd.aspetjournals.org Downloaded from
32
Table 5. Concentrations (ng equivalent/mL) and percentage of total radioactivity (in parentheses) of vabicaserin and metabolites in plasma of male mice, rats and dogs following a single oral administration.
Species Mice Rats Dogs Time (h) 2 4 8 2 4 8 4 8 24
Vabicaserin 0.58 (15.1) 0.46 (12.3) 0.38 (11.7) 86.9 (13.7) 90.8 (13.8) 58.7 (12.7) 90.2 (16.0) 4.75 (0.9) 21.9 (1.6) P1 ND ND ND 88.4 (14.0) 59.7 (9.1) 41.9 (8.9) 36.4 (6.5) 39.4 (7.5) 68.3 (5.1) P2 0.51 (13.4) 0.55 (14.7) 0.41 (12.7) 32.3 (5.2) 22.6 (3.4) 20.0 (4.3) 52.5 (9.3) ND 53.6 (4.0)
P3/M9 0.53 (13.8) 0.57 (15.0) 0.65 (19.8) 76.4 (12.1) 105 (16.0) 64.2 (13.8) 135 (24.0) 364 (69.0) 875 (65.3) P4 ND ND ND 28.3 (4.4) 28.3 (4.3) 12.4 (2.5) ND ND ND P5 ND ND ND ND ND ND 33.6 (6.0) 7.04 (1.3) ND P7 0.25 (6.6) 0.25 (6.5) 0.19 (5.7) 63.6 (10.1) 62.1 (9.4) 53.5 (11.5) 41.5 (7.4) ND 88.0 (6.6) P8 ND ND ND 15.1 (2.4) 30.3 (4.6) ND ND ND ND
P10 ND ND ND 11.6 (1.9) 14.2 (2.2) 6.33 (1.4) ND ND ND P11 ND ND ND 23.7 (3.6) 9.81 (1.5) 13.2 (2.9) ND ND ND P12 ND ND ND 37.2 (6.0) 34.5 (5.2) 16.3 (3.6) ND ND ND P13 ND ND ND ND ND ND 51.0 (9.1) 27.5 (5.2) ND P14 0.3 (7.9) 0.31 (8.2) 0.26 (8.0) ND ND ND CG 0.57 (14.9) 0.78 (20.6) 0.51 (15.7) ND ND ND 36.7 (6.5) 12.3 (2.3) 101 (7.5)
Others a 3.82 (28.3) 3.77 (22.7) 3.26 (26.5) 168 (26.4) 201 (31.0) 179 (38.4) 88.0 (15.6) 72.0 (13.6) 133 (9.9) Concentrations were estimated based on the total plasma radioactivity concentrations and the percent distribution of plasma radioactivity. a, sum of a number of uncharacterized minor metabolites each representing less than 5% of plasma radioactivity; ND, not detected.
DMD # 33670T
his article has not been copyedited and formatted. T
he final version may differ from
this version.D
MD
Fast Forward. Published on A
ugust 25, 2010 as DO
I: 10.1124/dmd.110.033670
at ASPET Journals on August 4, 2018 dmd.aspetjournals.org Downloaded from
33
Table 6. Distribution (% of dose) of vabicaserin and metabolites in urine of mice, rats and dogs.a Species vabicaserin P1 P2 b P3/P9 P4 P5 P7 P8 P11 P13 P14 P15 P16 P17 P18 CG Othersc Total Mouse 1.2 ND 19.2 7.1 ND ND 4.8 ND ND ND 3.2 1.9 3.0 2.3 ND 17.0 59.7
Rat 0.9 16.4 5.1 12.6 2.2 ND 6.6 2.6 2.0 ND ND ND ND ND ND ND 19.0 67.5 Dog 0.5 1.4 5.9 3.5 ND 0.3 0.8 ND ND 1.1 ND ND ND 2.1 0.9 1.9 8.7 26.9
a, Data represent 0-24 h for mice and rats and 0-48 h for dogs following oral administration; b, P19 co-eluted with P2 in mouse urine; c, A sum of a number of uncharacterized minor metabolites each representing less than approximately 3% of dose for mouse and rat, and 1.5% of dose for dog.
DMD # 33670T
his article has not been copyedited and formatted. T
he final version may differ from
this version.D
MD
Fast Forward. Published on A
ugust 25, 2010 as DO
I: 10.1124/dmd.110.033670
at ASPET Journals on August 4, 2018 dmd.aspetjournals.org Downloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 25, 2010 as DOI: 10.1124/dmd.110.033670
at ASPE
T Journals on A
ugust 4, 2018dm
d.aspetjournals.orgD
ownloaded from